)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Vir Biotechnology
Vir Biotechnology (VIR) investor relations material
Vir Biotechnology Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary6 May, 2026
Executive summary
Achieved major progress in oncology and hepatitis delta programs, including a landmark global collaboration with Astellas for VIR-5500, a PRO-XTEN dual-masked PSMA-targeted T-cell engager for prostate cancer, with a $240M upfront payment, $75M equity investment, and up to $1.37B in milestones and royalties.
Advanced hepatitis delta program with strong phase II data for tobevibart plus elebsiran, showing 88% undetectable HDV RNA at 96 weeks and favorable safety.
Strategic collaborations with Norgine and Astellas accelerate access and development of key assets, with Norgine providing €55M upfront and up to €495M in milestones for CHD therapy in Europe, Australia, and New Zealand.
Proprietary discovery engine and PRO-XTEN masking technology enable differentiated T-cell engager therapies, advancing multiple preclinical and clinical programs.
Completed $172.5M follow-on equity offering, further strengthening the balance sheet.
Financial highlights
Ended Q1 2026 with $809.3M in cash equivalents and investments, excluding $315M from Astellas collaboration to be received in Q2 2026.
Q1 2026 total revenues were $0, down from $3.0M in Q1 2025.
R&D expense for Q1 2026 was $108.9M, down from $118.6M in Q1 2025, mainly due to a prior $30M payment to Alnylam.
SG&A expense was $23.3M, slightly down from $23.9M year-over-year.
Net loss for Q1 2026 was $125.7M, compared to $121M in Q1 2025.
Outlook and guidance
Registrational phase III program for VIR-5500 expected to initiate in 2027; pivotal trials for prostate cancer anticipated to begin in 2027.
Top-line data from ECLIPSE 1 hepatitis delta study expected in Q4 2026; ECLIPSE 2 and 3 readouts in Q1 2027.
Filing for hepatitis delta regimen will require data from both ECLIPSE 1 and ECLIPSE 2.
Preliminary response data for VIR-5818 (HER2) expected in the second half of 2026.
Advancing 7 preclinical PRO-XTEN TCE targets toward development candidate selection by early 2027.
ECLIPSE 2 bulevirtide switch trial design
VIR-5500 Astellas cost sharing and profit split
VIR-5818 ctDNA molecular response significance
Sanofi's share of Astellas deal proceeds
ECLIPSE 1 vs ECLIPSE 2 patient populations
VIR-5500 Phase 3 trial initiation timeline
VIR-5500 use in pre- and post-RLT settings
HDV combination TND rates versus competitors
VIR-5525 differentiation from Janux EGFR asset
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vir Biotechnology
- Director elections, executive pay, and auditor ratification headline a governance-focused agenda.VIR
Proxy filing16 Apr 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor ratification.VIRProxy filing16 Apr 2026
- Astellas deal, strong VIR-5500 data, and licensing boost cash and pipeline for 2027 trials.VIRQ4 202511 Apr 2026
- Strong clinical data and partnerships drive rapid progress in oncology and hepatitis delta.VIRLeerink Global Healthcare Conference 202610 Mar 2026
- VIR-5500 delivers best-in-class efficacy and safety, driving expansion and pivotal trials in 2025.VIRTD Cowen 46th Annual Health Care Conference2 Mar 2026
- CHD therapy and masked TCEs show strong efficacy, safety, and value-driving milestones ahead.VIRCorporate presentation23 Feb 2026
- Durable HDV responses and a robust pipeline drive progress toward key milestones.VIRGoldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026
- Q2 net loss narrowed to $138.4M as restructuring and Sanofi deal sharpen focus on hepatitis and T-cell assets.VIRQ2 20242 Feb 2026
- Tobevibart and elebsiran show strong efficacy and safety in chronic hepatitis delta patients.VIRStudy Update31 Jan 2026
Next Vir Biotechnology earnings date
Bank of America Global Healthcare Conference 202612 May, 2026
Vir Biotechnology
Next Vir Biotechnology earnings date
Bank of America Global Healthcare Conference 202612 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage